In another study, elevated levels of PRMT5 were shown to reduce the tumour‐suppressor activity of PDCD4 in primary breast tumours by methylating its N‐terminal arginine residues, resulting in reduced patient survival.24 The gene discussed is PDCD4; the disease is neoplasm.